Apoptosis

Apoptosis(凋亡)

As one of the cellular death mechanisms, apoptosis, also known as programmed cell death, can be defined as the process of a proper death of any cell under certain or necessary conditions. Apoptosis is controlled by the interactions between several molecules and responsible for the elimination of unwanted cells from the body.

Many biochemical events and a series of morphological changes occur at the early stage and increasingly continue till the end of apoptosis process. Morphological event cascade including cytoplasmic filament aggregation, nuclear condensation, cellular fragmentation, and plasma membrane blebbing finally results in the formation of apoptotic bodies. Several biochemical changes such as protein modifications/degradations, DNA and chromatin deteriorations, and synthesis of cell surface markers form morphological process during apoptosis.

Apoptosis can be stimulated by two different pathways: (1) intrinsic pathway (or mitochondria pathway) that mainly occurs via release of cytochrome c from the mitochondria and (2) extrinsic pathway when Fas death receptor is activated by a signal coming from the outside of the cell.

Different gene families such as caspases, inhibitor of apoptosis proteins, B cell lymphoma (Bcl)-2 family, tumor necrosis factor (TNF) receptor gene superfamily, or p53 gene are involved and/or collaborate in the process of apoptosis.

Caspase family comprises conserved cysteine aspartic-specific proteases, and members of caspase family are considerably crucial in the regulation of apoptosis. There are 14 different caspases in mammals, and they are basically classified as the initiators including caspase-2, -8, -9, and -10; and the effectors including caspase-3, -6, -7, and -14; and also the cytokine activators including caspase-1, -4, -5, -11, -12, and -13. In vertebrates, caspase-dependent apoptosis occurs through two main interconnected pathways which are intrinsic and extrinsic pathways. The intrinsic or mitochondrial apoptosis pathway can be activated through various cellular stresses that lead to cytochrome c release from the mitochondria and the formation of the apoptosome, comprised of APAF1, cytochrome c, ATP, and caspase-9, resulting in the activation of caspase-9. Active caspase-9 then initiates apoptosis by cleaving and thereby activating executioner caspases. The extrinsic apoptosis pathway is activated through the binding of a ligand to a death receptor, which in turn leads, with the help of the adapter proteins (FADD/TRADD), to recruitment, dimerization, and activation of caspase-8 (or 10). Active caspase-8 (or 10) then either initiates apoptosis directly by cleaving and thereby activating executioner caspase (-3, -6, -7), or activates the intrinsic apoptotic pathway through cleavage of BID to induce efficient cell death. In a heat shock-induced death, caspase-2 induces apoptosis via cleavage of Bid.

Bcl-2 family members are divided into three subfamilies including (i) pro-survival subfamily members (Bcl-2, Bcl-xl, Bcl-W, MCL1, and BFL1/A1), (ii) BH3-only subfamily members (Bad, Bim, Noxa, and Puma9), and (iii) pro-apoptotic mediator subfamily members (Bax and Bak). Following activation of the intrinsic pathway by cellular stress, pro‑apoptotic BCL‑2 homology 3 (BH3)‑only proteins inhibit the anti‑apoptotic proteins Bcl‑2, Bcl-xl, Bcl‑W and MCL1. The subsequent activation and oligomerization of the Bak and Bax result in mitochondrial outer membrane permeabilization (MOMP). This results in the release of cytochrome c and SMAC from the mitochondria. Cytochrome c forms a complex with caspase-9 and APAF1, which leads to the activation of caspase-9. Caspase-9 then activates caspase-3 and caspase-7, resulting in cell death. Inhibition of this process by anti‑apoptotic Bcl‑2 proteins occurs via sequestration of pro‑apoptotic proteins through binding to their BH3 motifs.

One of the most important ways of triggering apoptosis is mediated through death receptors (DRs), which are classified in TNF superfamily. There exist six DRs: DR1 (also called TNFR1); DR2 (also called Fas); DR3, to which VEGI binds; DR4 and DR5, to which TRAIL binds; and DR6, no ligand has yet been identified that binds to DR6. The induction of apoptosis by TNF ligands is initiated by binding to their specific DRs, such as TNFα/TNFR1, FasL /Fas (CD95, DR2), TRAIL (Apo2L)/DR4 (TRAIL-R1) or DR5 (TRAIL-R2). When TNF-α binds to TNFR1, it recruits a protein called TNFR-associated death domain (TRADD) through its death domain (DD). TRADD then recruits a protein called Fas-associated protein with death domain (FADD), which then sequentially activates caspase-8 and caspase-3, and thus apoptosis. Alternatively, TNF-α can activate mitochondria to sequentially release ROS, cytochrome c, and Bax, leading to activation of caspase-9 and caspase-3 and thus apoptosis. Some of the miRNAs can inhibit apoptosis by targeting the death-receptor pathway including miR-21, miR-24, and miR-200c.

p53 has the ability to activate intrinsic and extrinsic pathways of apoptosis by inducing transcription of several proteins like Puma, Bid, Bax, TRAIL-R2, and CD95.

Some inhibitors of apoptosis proteins (IAPs) can inhibit apoptosis indirectly (such as cIAP1/BIRC2, cIAP2/BIRC3) or inhibit caspase directly, such as XIAP/BIRC4 (inhibits caspase-3, -7, -9), and Bruce/BIRC6 (inhibits caspase-3, -6, -7, -8, -9). 

Any alterations or abnormalities occurring in apoptotic processes contribute to development of human diseases and malignancies especially cancer.

References:
1.Yağmur Kiraz, Aysun Adan, Melis Kartal Yandim, et al. Major apoptotic mechanisms and genes involved in apoptosis[J]. Tumor Biology, 2016, 37(7):8471.
2.Aggarwal B B, Gupta S C, Kim J H. Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey.[J]. Blood, 2012, 119(3):651.
3.Ashkenazi A, Fairbrother W J, Leverson J D, et al. From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors[J]. Nature Reviews Drug Discovery, 2017.
4.McIlwain D R, Berger T, Mak T W. Caspase functions in cell death and disease[J]. Cold Spring Harbor perspectives in biology, 2013, 5(4): a008656.
5.Ola M S, Nawaz M, Ahsan H. Role of Bcl-2 family proteins and caspases in the regulation of apoptosis[J]. Molecular and cellular biochemistry, 2011, 351(1-2): 41-58.

研究方向

Apoptosis 相关产品(2721)

  • GC61745 structure
    GC61745AP1867-2-(carboxymethoxy)
    CAS: 2230613-03-1

    AP1867-2-(carboxymethoxy)是一种基于AP1867(一种合成的FKBP12F36V配体)的配体,可通过linker与CRBN配体结合从而形成dTAG分子。

  • GC61750 structure
    GC61750(Rac)-Indoximod
    CAS: 26988-72-7
    纯度: >97.00%

    (Rac)-Indoximod(1-Methyl-DL-tryptophan)是吲哚胺-2,3-双加氧酶(IDO)抑制剂。(Rac)-Indoximod和IFN-γ联用显著降低了表达α-SMA的人心肌成纤维细胞活性,并通过上调IRF-1,Fas和FasL基因诱导凋亡(apoptosis)。

  • GC61776 structure
    GC61776Ingenol 3,20-dibenzoate
    CAS: 59086-90-7
    纯度: >99.00%

    Ingenol3,20-dibenzoate是一种有效的蛋白激酶C(PKC)亚型选择性激动剂。Ingenol3,20-dibenzoate诱导nPKC-delta、-epsilon和-theta和PKC-mu从胞质部分选择性转移到颗粒组分,并通过从头合成大分子诱导形态上典型的凋亡(apoptosis)。Ingenol3,20-dibenzoate可促进NK细胞产生IFN-γ和脱颗粒,尤其是当NSCLC细胞刺激NK细胞时。

  • GC61777 structure
    GC61777RWJ-56110 dihydrochloride
    CAS: 2387505-58-8

    RWJ-56110dihydrochloride是一种有效的、选择性的、拟肽抑制剂,抑制PAR-1激活和内化(结合IC50=0.44uM),对PAR-2,PAR-3和PAR-4无影响。RWJ-56110dihydrochloride抑制由SFLLRN-NH2 (IC50=0.16μM)和凝血酶(IC50=0.34μM)诱导的血小板聚集,相对于U46619具有相当的选择性。RWJ-56110dihydrochloride在体内阻断血管生成和新血管的形成。RWJ-56110dihydrochloride诱导细胞凋亡(apoptosis)。

  • GC61799 structure
    GC61799Paeoniflorigenone
    CAS: 80454-42-8
    纯度: >98.00%

    Paeoniflorigenone是从牡丹皮中提取的一种有效成分,具有选择性诱导肿瘤细胞凋亡(apoptosis)和抗增殖作用。

  • GC61804 structure
    GC61804Amifostine thiol
    CAS: 31098-42-7
    纯度: >98.00%

    Amifostinethiol(WR-1065)是细胞保护剂Amifostine的活性代谢物。Amifostinethiol是一种具有辐射防护能力的细胞保护剂。Amifostinethiol通过JNK依赖的信号通路激活p53。

  • GC61809 structure
    GC61809Olanzapine D3
    CAS: 786686-79-1
    纯度: >99.00%

    OlanzapineD3(LY170053D3)是Olanzapine的氘代物。Olanzapine是一种选择性单胺能拮抗剂,高亲和力结合5-羟色胺H1,5HT2A/2C,5HT3,5HT6(Ki分别为7、4、11、57和5nM),多巴胺D1-4(Ki=11-31nM),毒蕈碱M1-5(Ki=1.9-25nM)和肾上腺素α1受体(Ki=19nM)。Olanzapine是一种非典型的抗精神病剂。

  • GC61865 structure
    GC61865Cearoin
    CAS: 52811-37-7
    纯度: >98.00%

    Cearoin 通过促进 ROS 产生和激活 ERK 来增强自噬 (autophagy) 和诱导细胞凋亡(apoptosis)。

  • GC61896 structure
    GC61896trans-Chalcone
    CAS: 614-47-1

    Trans-Chalcone, the backbone of flavonoids, also is a potent fatty acid synthase (FAS) with IC50 of 17.1 μg/mL, and α-amylase inhibitor, causes cellcycle arrest and induces apoptosis in the breastcancer cell line MCF-7, exerting antifungal and anticancer activities.

  • GC61945 structure
    GC61945PR-924
    CAS: 1416709-79-9

    PR-924 是一种选择性三肽环氧酮免疫蛋白酶亚单位 LMP-7 的抑制剂,IC50 为 22 nM。PR-924 共价修饰蛋白酶体的 N 端苏氨酸活性位点。PR-924 在多发性骨髓瘤细胞中抑制细胞生长并触发凋亡 (apoptosis),并具有抗肿瘤活性。

  • GC61946 structure
    GC61946TPP-1
    CAS: 2426685-25-6
    纯度: >96.50%

    TPP-1 是 PD-1/PD-L1 相互作用的有效抑制剂。TPP-1 与 PD-L1 特异性高亲和力结合 (KD=95 nM)。动物模型中,TPP-1 通过再激活 T 细胞功能抑制肿瘤生长。

  • GC61948 structure
    GC61948Inecalcitol
    CAS: 163217-09-2
    纯度: >98.00%

    Inecalcitol (TX 522) 是一种独特的维生素 D3 类似物,是一种具有口服活性维生素 D 受体 (VDR) 激动剂。Inecalcitol 可诱导细胞凋亡 (apoptosis),并具有有效的抗癌活性。

  • GC61995 structure
    GC61995PKCβ inhibitor 1
    CAS: 257879-35-9
    纯度: >98.00%

    A PKCβ Inhibitor

  • GC62033 structure
    GC620333α-Hydroxy pravastatin sodium
    CAS: 81093-43-8

    A metabolite of pravastatin

  • GC62104 structure
    GC62104WM-3835
    CAS: 2229025-70-9
    纯度: >98.00%

    WM-3835 is a novel and high-specific small molecule Lysine Acetyltransferase 7 (KAT7, MYST2, HBO1) inhibitor, able to potently suppressed OS cell proliferation and migration, and leads to apoptosis activation.

  • GC62111 structure
    GC62111PND-1186 hydrochloride
    CAS: 1356154-94-3
    纯度: >98.50%

    A potent FAK inhibitor

  • GC62125 structure
    GC62125PD-1/PD-L1-IN-10
    CAS: 2487550-41-2
    纯度: >99.00%

    PD-1/PD-L1-IN-10 (compound B2) 是具有口服活性的 PD-1/PD-L1 抑制剂 (IC50 of 2.7 nM),具有抗肿瘤活性。

  • GC62164 structure
    GC62164BAY1082439
    CAS: 1375469-38-7
    纯度: >99.00%

    An inhibitor of PI3Kα, PI3Kβ, and PI3Kδ

  • GC62167 structure
    GC62167Fluorizoline
    CAS: 1362243-70-6
    纯度: >99.50%

    Fluorizoline 选择性地直接结合到 prohibitin 1 (PHB1) 和 2 (PHB2),并诱导凋亡。Fluorizoline 通过上调 NOXA 和 BIM 降低慢性淋巴细胞性白血病 (CLL) 细胞的活力。Fluorizoline 以 p53 非依赖性方式发挥抗肿瘤作用。

  • GC62174 structure
    GC62174ON1231320
    CAS: 1312471-39-8
    纯度: >98.00%

    ON1231320 (7ao), an arylsulfonyl pyrido-pyrimidinone, is a highly specific inhibitor of polo like kinase 2 (PLK2). It also blocks tumor cell cycle progression in the G2/M phase in mitosis and causes apoptosis.

  • GC62186 structure
    GC62186KB02-SLF
    CAS: 2384184-40-9
    纯度: >99.00%

    KB02-SLF 是一种基于 PROTAC 的核 FKBP12 降解剂 (molecular glue)。KB02-SLF 通过共价修饰 DCAF16 (E3 ligase) 促进 FKBP12 降解,并可以提高生物系统中蛋白质降解的持久性。KB02-SLF 由 SLF 与泛素 E3 连接酶配体 (KB02) 通过 linker 连接而成。

  • GC62191 structure
    GC62191TD52
    CAS: 1798328-24-1
    纯度: >99.00%

    A derivative of erlotinib

  • GC62192 structure
    GC62192COG1410
    CAS: 878009-24-6
    纯度: >98.00%

    COG1410 是一种载脂蛋白 E 的衍生肽。COG1410 在小鼠颅脑损伤 (TBI) 模型中发挥神经保护和抗炎作用。COG1410 可用于神经系统疾病的研究。

  • GC62193 structure
    GC62193(1S,2S)-Bortezomib
    CAS: 1132709-14-8
    纯度: >96.00%

    (1S,2S)-Bortezomib 是 Bortezomib 的对映异构体。Bortezomib 是一种细胞渗透性、可逆性和选择性的蛋白酶体抑制剂,通过靶向苏氨酸残基有效抑制 20S 蛋白酶体 (Ki 为 0.6 nM)。Bortezomib 破坏细胞周期、诱导细胞凋亡以及抑制核因子 NF-κB。Bortezomib 是一种抗癌药物,也是第一种用于人类的蛋白酶体抑制剂。